GVR Report cover Autoimmune Treatment Market Size, Share & Trends Report

Autoimmune Treatment Market Size, Share & Trends Analysis Report By Application, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Historical Data: ---
  • Forecast Period: 1 - 2025 
  • Industry: Healthcare

The global autoimmune treatment market is anticipated to witness growth over the forecast period. Rising prevalence of autoimmune diseases is the major driver attributing towards the growth of the market. As per the statistics published by the National Institute of Health (NIH), around 23.5 million people in the U.S. alone suffer from autoimmune disease thereby leading to increasing need of developing apt treatment procedures and devices. Furthermore, slow turnaround associated with the autoimmune disease diagnostics procedures is also affecting the market growth positively. Rising public awareness towards the availability of various alternatives for treatment is expected to further boost the market growth during the forecast period. Growing initiatives by the government and pharmaceutical companies to enhance the R&D initiatives to develop new drugs and therapies is expected to boost the market in the coming six years.

The autoimmune treatment market is bifurcated on the basis of application into localized autoimmune diseases and systemic autoimmune diseases. The systematic autoimmune disease is further sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others. Rheumatoid arthritis dominated the market under the systemic autoimmune diseases segment. Rising prevalence of this disease coupled with growing patient awareness levels accounted for the major share of this market. Multiple sclerosis, dominated the market under localized autoimmune disease. On the basis of products the market is segmented into diagnostic equipments, drugs, and therapeutic & monitoring equipment. Some major drugs analyzed in the study include non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, methotrexate, anthralin, avonex, and hydroxychloroquine (HCQ). The drugs as well as therapy & monitoring market is expected to grow substantially, due to the fact that almost all the autoimmune diseases are chronic in nature with no permanent cure.

Regionally North America dominated the autoimmune treatment market. Availability of high disposable income with the population of this region along with the presences of a large patient base suffering from various autoimmune disorders contributed towards the growth of this region. Asia Pacific is expected to witness substantial growth during the forecast period as a consequence of rapidly improving healthcare infrastructure coupled with rising patient awareness levels regarding the early treatment of the autoimmune disorders.

The major companies operating in the global autoimmune treatment market are Abbott Laboratories, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, Roche, Astrazeneca Plc, and Bristol-Myers Squibb Co. The market of autoimmune treatments is consolidated and the companies are involved in developing novel drugs and technology to maintain their pace and retain a substantial share in the market. 

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.